Top

Kanishka Sircar, M.D.

Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div

About Dr. Kanishka Sircar

Dr. Sircar's research interests include functional genomic studies of advanced therapy resistant prostatic carcinoma and sarcomatoid renal cell carcinoma.

Primary Appointment

Professor, Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1994	McGill University, Montreal, Quebec, CA, MDCM in Medicine
1990	McGill University, Montreal, Quebec, CA, Med-P in Pre-Med

Postgraduate Training

2001-2002	Clinical Fellowship, Genitourinary Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
2000-2001	Clinical Fellowship, Oncologic Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
1995-1999	Clinical Residency, Anatomical Pathology, McMaster University, Hamilton, Ontario
1994-1995	Clinical Internship, Rockyview General Hospital, Calgary, Alberta

Licenses & Certifications

2008	Texas Medical Board
2002	American Board of Pathology, Anatomic Pathology
1999	Anatomical Pathology, Specialist Certificate, College des Medecins du Quebec
1999	Anatomical Pathology, Royal College of Physicians and Surgeons of Canada (FRCPC)
1996	MCCQE

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2018

Associate Professor, Department of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018

Assistant Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2012

Associate Member, Department of Urology, McGill University, Montreal, 2006 - 2008

Assistant Professor, Department of Pathology, McGill University, Montreal, 2002 - 2008

Lecturer, McGill University, Montreal, 1999 - 2000

Administrative Appointments/Responsibilities

Representative, Workforce Communities & Connections Council, Department of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2025 - Present

Chair, Diversity, Equity and Inclusion Committee, Department of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023

Other Professional Positions

Associate Editor, Journal of the National Comprehensive Cancer Network, Houston, TX, 2018 - Present

Panelist, National Comprehensive Cancer Network Testicular Cancers Panel, Houston, TX, 2016 - Present

Panelist, National Comprehensive Cancer Network Kidney and Testicular Cancers Panel, Houston, TX, 2011 - 2016

Examiner, Anatomic Pathology, Royal College of Physicians and Surgeons of Canada, Ottawa, 2008 - 2009

Coordinator, McGill University Health Center Quebec Biobank Prostate Tissue Collection Network, Montreal, 2007 - 2008

Staff Pathologist and Director, Genitourinary Pathology, McGill University Health Center, Montreal, 2006 - 2008

Consultant, Caprion Pharmaceuticals, Inc, Montreal, Canada, 2005 - 2007

Consultant, Proscan Pharmaceuticals, Montreal, Canada, 2004 - 2005

Staff Pathologist, Royal Victoria Hospital, Montreal, 1999 - 2000

Extramural Institutional Committee Activities

Member, Executive Committee Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, MD Anderson Cancer Network GU Pathology representative, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, Executive Operations Committee Department of Pathology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Translational Molecular Pathology Distinguished Speaker Committee, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Surgical Pathology Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2016 - 2019

Member, Genitourinary Pathology Fellowship Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2016 - Present

Member, Faculty Academic Review Committee, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2015 - Present

Member, Institutional Review Board 1, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2009 - 2015

Member, Pathology Residency Training Committee, McGill University Health Center, The University of Texas MD Anderson Cancer Center, 2002 - 2008

Editorial Activities

Associate Editor, Journal of the National Comprehensive Cancer Network, 2018 - Present

Peer Review Panel Member, European Medical Journal Oncology, 2017 - Present

Editorial Board Member, Journal of Clinical and Experimental Pathology, 2011 - Present

Honors & Awards

2018	Shirley Stein Scientific Endowment Research Award, The University of Texas MD Anderson Cancer Center
2004 - 2006	William Duguid Award in Pathology, MUHC Research Institute
1998	Most Meritorious Resident Presentation at USCAP, Gastrointestinal Pathology Society (of America)
1998	Resident Research Award, Canadian Society of Clinical Investigation
1998	Resident Research Award, Physicians Services Incorporated
1989 - 1992	J.W. McConnell Award

Professional Memberships

Harris County Medical Society

2009 - Present

International Society of Urological Pathology

2006 - 2017

United States and Canadian Academy of Pathology

2005 - Present

Royal College of Physicians and Surgeons of Canada

2003 - 2010

Federation de Medecins Specialistes de Quebec (FMSQ)

2002 - 2008

Selected Presentations & Talks

Local Presentations

2025. MD Anderson Cancer Network GU Oncology. Conference. Integration Retreat. Houston, Texas, US.
2023. MD Anderson Cancer Network GU Oncology. Conference. Integration Retreat. Houston, TX, US.
2022. MD Anderson Cancer Network GU Oncology. Conference. Integration Retreat. Houston, TX, US.
2021. MD Anderson Cancer Network GU Oncology. Conference. Integration Retreat. Houston, TX, US.
2020. MD Anderson Cancer Network GU Oncology. Conference. Integration Retreat. Houston, TX, US.
2019. MD Anderson Cancer Network GU Oncology. Conference. Integration Retreat. Houston, TX, US.
2019. Global Academic Programs Conference, The molecular basis of Sarcomatoid Renal Cell Carcinoma. Conference. Global Academic Programs Conference, The molecular basis of Sarcomatoid Renal Cell Carcinoma. Houston, TX, US.
2018. Translational Molecular Pathology Retreat, Improved patient Outcomes: Morphologic and Molecular Examination of Low-Risk and High-Risk Renal Masses. Conference. Translational Molecular Pathology Retreat, Improved patient Outcomes: Morphologic and Molecular Examination of Low-Risk and High-Risk Renal Masses. Houston, TX, US.
2016. Translational Molecular Pathology Retreat. Conference. Translational Molecular Pathology Retreat. Houston, TX, US.
2016. Kidney SPORE Internal Advisory Meeting. Conference. Kidney SPORE Internal Advisory Meeting. Houston, TX, US.
2015. Kidney SPORE Planning Meeting. Conference. Kidney SPORE Planning Meeting. Houston, TX, US.
2014. Kidney SPORE. Conference. Kidney SPORE. Houston, TX, US.
2013. Kidney Cancer Collaborative Symposium. Conference. Kidney Cancer Collaborative Symposium. Houston, TX, US.
2012. Grand Rounds. Conference. Grand Rounds. Houston, TX, US.
2012. Kidney SPORE Working Group. Conference. Kidney SPORE Working Group. Houston, TX, US.
2012. Diagnostic Pathology Course. Conference. Diagnostic Pathology Course. Houston, TX, US.
2011. Koch Center External Advisory Board. Conference. Koch Center External Advisory Board. Houston, TX, US.
2010. Zhang Laboratory Seminar. Conference. Zhang Laboratory Seminar. Houston, TX, US.
2010. Genitourinary Research Working Group. Conference. Genitourinary Research Working Group. Houston, TX, US.

National Presentations

2024. Spatial transcriptomic evaluation of tumor and tumor microenvironment of renal cell carcinoma with respect to regional histology and response to immunotherapy (platform presentation). Conference. United States and Canadian Academy of Pathology (USCAP). Baltimore, MD, US.
2022. Department of Pathology. Invited. San Diego, CA, US.
2022. MAGE Family of Cancer Testis Antigen Genes are Associated with Resistance in Immune Checkpoint Inhibitors on Sarcomatoid Renal Cell Carcinomas (poster). Conference. Los Angeles, CA, US.
2022. Single Region Sampling Does Not Capture The Intra-Tumoral Immune Heterogeneity of Sarcomatoid Renal Cell Carcinoma (poster). Conference. Los Angeles, CA, US.
2021. Gene Methylation Patterns of Aggressive Chromophobe Renal Cell Carcinoma (poster). Conference.
2020. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era (poster). Conference. Los Angeles, CA, US.
2019. Department of Pathology. Invited. Houston, TX, US.
2019. Manual Estimation of Tumor Purity is Poor Compared to Sequencing-Based Estimates (platform presentation). Conference. National Harbor, MD, US.
2017. Grand Rounds. Invited. Los Angeles, CA, US.
2017. Department of Pathology. Invited. Spokane, WA, US.
2017. Characterization of Driver Mutations in Hybrid Renal Oncocytic Tumors (platform presentation). Conference. San Antonio, TX, US.
2016. Department of Pathology. Invited. Minneapolis, MN, US.
2016. Sarcomatoid Clear Cell RCC Shows a Distinct Molecular Pathogenesis and Driver Mutation Profile (platform presentation). Conference. Seattle, WA, US.
2015. Prostate Cancer: Diagnosis, Biology, Pathology and Biomarkers. Conference. Houston, TX, US.
2015. Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma Pose a Challenge for Personalized Cancer Therapy (poster). Conference. Boston, MA, US.
2014. The Epithelioid and Sarcomatoid Components of Sarcomatoid RCC Are Molecularly Similar to Each Other but Distinct from Fuhrman Grade 4 Non-Sarcomatoid RCC (platform presentation). Conference. San Diego, CA, US.
2014. Rhabdoid RCC Is Molecularly Distinct from Fuhrman Grade 4 RCC (poster). Conference. San Diego, CA, US.
2013. Sarcomatoid and Rhabdoid RCC Show a Similar, Poor Prognosis Molecular Signature That Is Separable from Non-Sarcomatoid RCC (poster). Conference. Baltimore, MD, US.
2012. Journal Club. Invited. Santa Monica, CA, US.
2011. Resident Teaching Seminar. Invited. Los Angeles, CA, US.
2011. P01 Pacific Northwest SPORE Seminar. Invited. Seattle, WA, US.
2011. Asparagine Synthetase Is a Target in Castration Resistant Prostate Cancer (platform presentation). Conference. San Antonio, TX, US.
2010. Integrative Molecular Profiling of Castration Resistant Prostate Cancer (poster). Conference. Washington, DC, US.
2010. Virtual Karyotyping with SNP Arrays Identifies Chromosomal Imbalances as Biomarkers for Tumor Progression in Clear Cell Renal Cell Carcinoma (poster). Conference. Washington, DC, US.
2009. Oncofetal (IMP3) and Stem Cell Markers in Primary and Metastatic Renal Cell Carcinoma (poster). Conference. Boston, MA, US.
2009. YKL-40 as a Marker of Epithelial to Mesenchymal Transitional in Primary and Metastatic Renal Cell Carcinoma (poster). Conference. Boston, MA, US.
2008. PTEN gene dosage affects downstream AKT pathway in hormone refractory prostate cancer (poster). Conference. Denver, CO, US.
2008. Activation status of the PI3K/AKT/mTOR pathway in metastatic renal cell carcinomas and their matched primary tumors (poster). Conference. Denver, CO, US.
2007. Pathology Seminar. Invited. Houston, TX, US.
2007. Surgical Pathology Seminar. Invited. Palo Alto, CA, US.
2007. Multiple anti-cancer target expression in hormone refractory prostate cancer (poster). Conference. San Diego, CA, US.
2007. Novel Anti-PSMA monoclonal antibodies show superior tissue specificity (poster). Conference. San Diego, CA, US.
2006. Genetic heterogeneity of androgen sensitive and androgen independent prostate cancer: an analysis of androgen receptor CAG repeat lengths in germline, somatic and hormone refractory prostate cancer tissues (poster). Conference. Atlanta, GA, US.
2006. Mirror image banking of radical prostatectomy specimens enables isolation of epithelial plasma membranes for proteomics while preserving pathologic quality of retrieved tissues (poster). Conference. Atlanta, GA, US.
2005. Androgen receptor CAG tract heterogeneity in benign and malignant prostatic glands (poster). Conference. San Antonio, TX, US.
2005. Comparative study of immunohistochemical profiles of fetal and adult nephrons using renal tumor markers (poster). Conference. San Antonio, TX, US.
2002. Negative repeat biopsy of prostate cancer patients predicts for low volume, low stage disease (platform presentation). Conference. Chicago, IL, US.
2002. Seminomatous and nonseminomatous differential of mixed germ cell tumors of the testis: an immunohistochemical study of 24 cases (platform presentation). Conference. Chicago, IL, US.
1999. Kit immunoreativity of melanocytic lesions: an analysis of conventional nevi, Spitz and Reed's nevi and malignant melanoma (poster). Conference. New Orleans, LA, US.
1999. Differentiation of diminutive and partially myoid gut stromal tumors (poster). Conference. San Francisco, CA, US.
1998. Most Gastrointestinal Stromal Tumors Arise from Interstitial Cells of Cajal (platform presentation). Conference. Boston, MA, US.

International Presentations

2024. Testicular germ cell tumors: a clinicopathologic approach. Conference. Lisbon Pathology Update: 4th Edition. Lisbon, PT.
2024. Side Seminar on Gynecological, Lung, Genitourinary, Lymph Nodes and Breast Pathology. Conference. Lisbon Pathology Update: 4th Edition. Lisbon, PT.
2024. Renal cell carcinoma with mixed histology: a contemporary approach. Conference. Lisbon Pathology Update: 4th Edition. Lisbon, PT.
2023. U54 MD Anderson Cancer Center/UPR Partnership Program. Invited. San Juan, PR.
2019. Molecular Oncology Research Center. Invited. Barretos, BR.
2018. Side Seminar on Prostate, Kidney and Testicular Tumors. Conference. Lima, PE.
2018. Pathology of Adrenal, Upper Urothelial, Tract, Bladder, Prostate, and Kidney. Conference. Lima, PE.
2018. Department of Pathology. Invited. Kolkata, IN.
2018. Short Course on Genitourinary Pathology. Conference, SG.
2018. Slide Seminar on Genitourinary Pathology. Conference, SG.
2018. Hybrid Oncocytic Renal Tumors Display A Molecular Profile Intermediate Between Oncocytoma And Chromophobe Renal Cell Carcinoma (platform presentation). Conference. Vancouver, CA.
2018. Diagnostic evaluation of renal cell carcinoma. Conference. Gold Coast, AU.
2018. Genitourinary of Pathology case conference. Invited. Melbourne, AU.
2017. Department of Pathology. Invited. Kolkata, IN.
2017. A contemporary approach to renal cell carcinoma with mixed morphologic features. Conference. Copenhagen, DK.
2017. Testicular germ cell tumors: a clinicopathologic approach. Conference. Copenhagen, DK.
2017. Renal cell carcinoma: tumor grading and oncocytic neoplasms, morphologic and molecular considerations. Conference. Copenhagen, DK.
2017. Department of Pathology. Invited. Kolkata, IN.
2017. A clinicopathologic approach to evaluating testicular germ cell tumors. Conference. Mexico City, MX.
2017. Morphologic and molecular considerations in grading renal cell carcinoma and evaluating oncocytic lesions. Conference. Mexico City, MX.
2016. Renal cell carcinoma: A morphologic and molecular understanding of aggressive and indolent tumors. Conference. Madrid, ES.
2016. Testis: Testicular germ cell tumors: what pathologists need to know. Conference. Antigua, GT.
2016. Kidney: An update on contemporary challenges in the diagnosis and reporting of renal cell carcinoma. Conference. Antigua, GT.
2015. Slide Discussion: Testis Pathology. Conference. Warsaw, PL.
2015. Renal Cell Carcinoma: Tumor Grade and Oncocytic Neoplasms. Conference. Warsaw, PL.
2015. Slide Discussion: Bladder Pathology. Conference. Warsaw, PL.
2015. Testicular Germ Cell Tumors: A Clinicopathologic Approach. Conference. Warsaw, PL.
2015. Slide Discussion: Prostate Pathology. Conference. Warsaw, PL.
2015. Department of Pathology. Invited. Adana, TR.
2014. Department of Pathology. Invited. Xian, CN.
2013. Laboratory Medicine and Pathology Grand Rounds. Invited. Edmonton, CA.
2012. Mitosis Phase Enrichment with Identification of Mitotic Centromere-Associated Kinesin as a Therapeutic Target in Castration-Resistant Prostate Cancer (poster). Conference. Vancouver, CA.
2012. Sarcomatoid Renal Cell Carcinoma Shows a Distinct Transcriptomic Profile That Is Not Associated with Epithelial to Mesenchymal Transition Makers (poster). Poster. Vancouver, CA.
2008. Quebec Biobank Symposium. Invited. Quebec City, CA.
2007. Tissue Banking Seminar. Invited. Alberta, CA.
2007. Pathology of Renal Cell Carcinoma. Conference. Montreal, CA.
2007. Pathology of Testicular Neoplasia. Conference. Montreal, CA.
2007. Pathology of Prostatic Carcinoma. Conference. Montreal, CA.
2007. Pathology of Urothelial Carcinoma. Conference. Montreal, CA.
2007. MUHC symposium on Urologic malignancies. Invited. Quebec City, CA.
2006. Pathology of Urothelial Carcinoma. Conference. Montreal, CA.
2006. Pathology of Testicular Neoplasia. Conference. Montreal, CA.
2006. Pathology of Renal Cell Carcinoma. Conference. Montreal, CA.
2006. Pathology of Prostatic Carcinoma. Conference. Montreal, CA.
2005. Pathology of Testicular Neoplasia. Conference. Montreal, CA.
2005. Pathology of Prostatic Carcinoma. Conference. Montreal, CA.
2005. Pathology of Urothelial Carcinoma. Conference. Montreal, CA.
2005. Pathology of Renal Cell Carcinoma. Conference. Montreal, CA.
2005. Genitourinary Oncology Research Seminar. Invited. Quebec City, CA.
2004. Pathology of Renal Cell Carcinoma. Conference. Montreal, CA.
2004. Pathology of Urothelial Carcinoma. Conference. Montreal, CA.
2004. Surgery Rounds. Invited. Kolkata, IN.
2003. Pathology of Urothelial Carcinoma. Conference. Montreal, CA.
2003. Pathology of Renal Cell Carcinoma. Conference. Montreal, CA.
2003. Combined Rounds Pathology Lecture. Invited. Quebec City, CA.
1998. Plasmacytoid Transitional Cell Carcinoma of the Bladder (poster). Conference. Toronto, CA.

Formal Peers

2024. Side Seminar on Gynecological, Lung, Genitourinary, Lymph Nodes and Breast Pathology. Lisbon, PT.
2023. U54 MD Anderson Cancer Center/UPR Partnership Program. Invited. San Juan, PR.
2022. Department of Pathology. Invited. San Diego, CA, US.
2019. Molecular Oncology Research Center. Invited. Barretos, BR.
2019. Department of Pathology. Invited. Houston, TX, US.
2019. Department of Pathology. Invited. Kolkata, IN.
2018. Department of Pathology. Invited. Kolkata, IN.
2018. Genitourinary Pathology case conference. Invited. Melbourne, AU.
2017. Grand Rounds. Invited. Los Angeles, CA, US.
2017. Department of Pathology. Invited. Kolkata, IN.
2017. Department of Pathology. Invited. Spokane, WA, US.
2016. Department of Pathology. Invited. Minneapolis, MN, US.
2015. Department of Pathology. Invited. Adana, TR.
2014. Department of Pathology. Invited. Xian, CN.
2013. Laboratory Medicine and Pathology Grand Rounds, Cross Cancer Institute. Invited. Edmonton, CA.
2012. Journal Club. Invited. Santa Monica, CA, US.
2011. Resident Teaching Seminar. Invited. Los Angeles, CA, US.
2011. P01 Pacific Northwest SPORE Seminar. Invited. Seattle, WA, US.
2008. Quebec Biobank Symposium. Invited. Montreal, QC, CA.
2007. Tissue Banking Seminar. Invited. Edmonton, Alberta, CA.
2007. Pathology Seminar. Invited. Houston, TX, US.
2007. Surgical Pathology Seminar. Invited. Palo Alto, CA, US.
2007. MUHC symposium on Urologic malignancies. Invited. Montreal, Quebec, CA.
2005. Genitourinary Oncology Research Seminar. Invited. Montreal, QC, CA.
2004. Surgery Rounds. Invited. Kolkata, IN.
2003. Combined Rounds Pathology Lecture. Invited. Montreal, QC, CA.

Less

Grant & Contract Support

Date:	2024 - 2028
Title:	Targeted Modulation of Dendritic Cells in Lymph Nodes: Vaccines Against Kidney Cancer
Funding Source:	DoD/CDMRP
Role:	Co-I
ID:	KC230175

Date:	2023 - 2026
Title:	Phase I/II study of CAR.70- engineered IL15-transduced cord blood-derived NK cells in conjunction with lymphodepleting chemotherapy for the management of advanced renal cell carcinoma, mesothelioma and osteosarcoma
Funding Source:	MD Anderson Cancer Center Accelerator Fund
Role:	Collaborator
ID:	MDA 2021-0443

Date:	2021 - 2022
Title:	Investigating Tumor and Microenvironment Biomarkers in Sarcomatoid Renal Cell Carcinomas Treated with Immune Checkpoint Inhibitors
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Faculty Mentor (Student K. Ebare M.D.)

Date:	2020 - 2028
Title:	Kidney Cancer Clinical Trials Consortium
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	W81XWH2020020

Date:	2020 - 2023
Title:	Informatics for Functional Integration of Heterogeneous Cancer Genome and Transcriptome Sequencing Data
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5U01CA247760-01

Date:	2020 - 2022
Title:	CPRIT Early Clinical Investigator Award
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP20069

Date:	2019 - 2022
Title:	Molecular Profiling of Renal Oncocytic Neoplasms to develop Diagnostic and Prognostic Biomarkers
Funding Source:	Sister Institution Network (SNIF)
Role:	PI

Date:	2017 - 2020
Title:	Prognostic and Predictive Markers of Immunogenicity on Renal Cell Carcinoma
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	W81XWH-17-1-0307

Date:	2017 - 2018
Title:	Molecular Profiling of Aggressive Chromophobe Renal Cell Carcinoma to Develop Diagnostic and Prognostic Biomakers
Funding Source:	The Unversity of Texas MD Anderson Cancer Center
Role:	Faculty Mentor (Student: N. Alouch, M.D.)

Date:	2016 - 2016
Title:	Characterization of Driver Mutations in Hybrid Renal Oncocytic Tumors
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Faculty Mentor (Student: R. Ruiz-Cordero, M.D.)

Date:	2014 - 2017
Title:	Molecular Characterization of Sarcomatoid Change in Non-Clear Cell Renal Cell Carcinoma
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2014 - 2019
Title:	Pathology and Biospecimen Core
Funding Source:	Multi-Institutional Kidney Cancer, SPORE
Role:	Director

Date:	2013 - 2016
Title:	Sarcomatoid Change in Renal Cell Carcinoma
Funding Source:	Robert J. Kieberg Jr. and Helen C Kieberg Foundation
Role:	PI
ID:	CCSG grant CA016672 and the Khalifa Bin Zayed Al Nahyan Foundation

Date:	2013 - 2016
Title:	Sarcomatoid Change in Renal Cell Carcinoma
Funding Source:	Robert J. Kleberg,Jr. and Helen C. Kleberg Foundation, CCSG grant CA016672 and the Khalifa Bin Zayed Al Nahyan Foundation
Role:	PI

Date:	2013 - 2016
Title:	Molecular Characterization of Sarcomatoid Change in Renal Cell Carcinoma to Develop Biomarkers and Therapeutic Targets
Funding Source:	Kidney Cancer Research Program (Monteleone Foundation)
Role:	PI

Date:	2013 - 2013
Title:	Molecular Characterization of Rhabdoid Change in Renal Cell Carcinoma
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Faculty Mentor (Student: P. Murugan, M.D.)

Date:	2013 - 2014
Title:	Metabolic Targeting of Castration Resistant prostate cancer using Asparagine amino acid deprivation
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	PC121345

Date:	2012 - 2015
Title:	Identifying therapeutic targets in lethal prostate cancer using functional genomics Proposal #PC110964
Funding Source:	Department of Defense (DOD)
Role:	Principal Investigator-MDACC
ID:	10950601

Date:	2011 - 2014
Title:	Predicting human disease genes through integrative diseasome, genomics and proteomics
Funding Source:	National Science Foundation
Role:	Principal Investigator-MDACC
ID:	NSF-11-502

Date:	2011 - 2012
Title:	Identification and Characterization of Novel Therapeutic Targets in Castrate Resistant Prostate Cancer
Funding Source:	SPORE
Role:	PI

Date:	2009 - 2011
Title:	Integrative molecular profiling of hormone refractory prostate cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	1-RC1-CA144765-01

Date:	2008 - 2013
Title:	Epithelial mesenchymal transition in renal cell carcinoma
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2006 - 2009
Title:	Novel knock-in mouse models to study androgen receptor CAG repeat instability in prostate cancer
Funding Source:	National Cancer Institute of Canada (NCIC)
Role:	Co-I

Date:	2005 - 2007
Title:	Proteomic characterization of prostate, kidney and bladder cancer epithelium
Funding Source:	Caprion Pharmaceuticals, Inc
Role:	PI

Date:	2005 - 2006
Title:	Viventia bladder cancer trial
Funding Source:	Viventia
Role:	Study Pathologist

Date:	2004 - 2006
Title:	Development of transgenic mouse model to investigate the role of the androgen receptor and its CAG repeat in human prostate cancer
Funding Source:	US Army Medical Research and Material Command
Role:	Study pathologist

Date:	2004 - 2007
Title:	Pathology Research Grant
Funding Source:	MUHC Research Grant
Role:	PI

Date:	2003 - 2005
Title:	Antigenics renal carcinoma trial
Funding Source:	Antigenics
Role:	Study pathologist

Selected Publications

Peer-Reviewed Articles

Msaouel, P, Yu, K, Yuan, Y, Chen, J, Yan, X, Karki, M, Duan, F, Sheth, RA, Rao, P, Sircar, K, Shah, AY, Zurita-Saavedra, A, Genovese, G, Li, M, Yeh, CC, Dang, M, Han, G, Chu, Y, Hallin, M, Olson, P, Yang, R, Slavin, D, Der-Torossian, H, Chin, CD, Tannir, NM, Wang, L, Gao, J. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 39794332.
Ruiz-Cordero R, Wang Q, Kumar G, Akgul M, Creighton CJ, Rao P, Tamboli P, Zheng L, Zhao J, Murugan P, Shen S, Brimo F, Ezhilarasan R, Sulman E, Wani K, Lazar AJ, Kim T, Chen K, Bhat KPL, Kannan K, Wang J, Karam JA, Sircar K. Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples. Eur Urol Oncol 8(6):1629-1638, 2025. e-Pub 2025. PMID: 41193273.
Tang C, Sherry AD, Seo A, Hara K, Choi H, Liu S, Sun X, Montoya A, Ludmir EB, Shah AY, Jonasch E, Zurita AJ, Kovitz C, Alhalabi O, Goswami S, Hahn AW, Campbell MT, Hernandez A, Nead KT, Van Loo P, Su S, Battey CJ, LaBella ML, Ratzel S, Acevedo A, Genovese G, Sircar K, Karam JA, Tannir NM, Msaouel P. Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial. Lancet Oncol 26(10):1289-1299, 2025. e-Pub 2025. PMID: 40915303.
Gilligan, TD, Lin, DW, Adra, N, Bagrodia, A, Feldman, DR, Yamoah, K, Aggarwal, R, Chandrasekar, T, Costa, D, Drakaki, A, Eggener, SE, Emamekhoo, H, Geynisman, DM, Graham, LS, Humphrey, P, Leuva, H, Levine, EG, Luckenbaugh, AN, Maughan, B, McGregor, BA, Monk, P, Picus, J, Pierorazio, P, Rais-Bahrami, S, Reichert, ZR, Rwigema, JM, Saylor, P, Shah, A, Shah, SA, Singla, N, Sircar, K, VanderWeele, D, Zhumkhawala, A, Montgomery, S, Sliker, B. Testicular Cancer, Version 2.2025 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network 23(4), 2025. e-Pub 2025. PMID: 40203876.
Moussa, MJ, Khandelwal, J, Wilson, NR, Malikayil, KL, Surasi, DS, Bathala, TK, Lin, Y, Rao, P, Tamboli, P, Sircar, K, Ajufo, HO, Elsayes, KM, Shah, AY, Johns, AC, Goswami, S, Hasanov, E, Jonasch, E, Msaouel, P, Campbell, M, Alhalabi, O, Tannir, NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. Journal for immunotherapy of cancer 13(2), 2025. e-Pub 2025. PMID: 39939142.
Bhat, P, Tamboli, P, Sircar, K, Kannan, KS. Spatial Distribution of Tumor Cells in Clear Cell Renal Cell Carcinoma Is Associated with Metastasis and a Matrisome Gene Expression Signature. Cancers 17(2), 2025. e-Pub 2025. PMID: 39858031.
Serrano AG, Rocha P, Lima CF, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM. Delta-like Ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol 8(1):268, 2024. e-Pub 2024. PMID: 39558076.
Hahn AW, Surasai D, Vicuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Johasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2024. PMID: 38035767.
Hwang MJ, Brennan PM, Monge BM, Alkamachi B, Rohra P, Peshoff MM, Sharma P, Sircar K, Tamboli P, Rao P. Best practices and recommendations for grossing and reporting of post-immunotherapy nephrectomy specimens. Diagn Histopathol 30(5):275-281, 2024. e-Pub 2024.
Perelli, L, Carbone, F, Zhang, L, Huang, JK, Le, C, Khan, H, Citron, F, Del Poggetto, E, Gutschner, T, Tomihara, H, Soeung, M, Minelli, R, Srinivasan, S, Peoples, M, Lam, TA, Lundgren, S, Xia, R, Zhu, C, Mohamed, AM, Zhang, J, Sircar, K, Sgambato, A, Gao, J, Jonasch, E, Draetta, G, Futreal, A, Bakouny, Z, Van Allen, EM, Choueiri, TK, Signoretti, S, Msaouel, P, Litchfield, K, Turajlic, S, Wang, L, Chen, YB, Di Natale, RG, Hakimi, AA, Giuliani, V, Heffernan, TP, Viale, A, Bristow, C, Tannir, NM, Carugo, A, Genovese, G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nature Cancer 4(7):984-1000, 2023. e-Pub 2023. PMID: 37365326.
Alhalabi, O, Thouvenin, J, Negrier, S, Vano, Y, Campedel, L, Hasanov, E, Bakouny, Z, Hahn, AW, Bilen, MA, Msaouel, P, Choueiri, TK, Viswanathan, SR, Sircar, K, Albiges, L, Malouf, GG, Tannir, NM. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. Oncologist 28(5):433-439, 2023. e-Pub 2023. PMID: 36640141.
Falahkheirkhah, K, Guo, T, Hwang, M, Tamboli, P, Wood, CG, Karam, JA, Sircar, K, Bhargava, R. A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Laboratory Investigation 102(5):554-559, 2022. e-Pub 2022. PMID: 34963688.
Msaouel, P, Goswami, S, Thall, PF, Wang, X, Yuan, Y, Jonasch, E, Gao, J, Campbell, M, Shah, AY, Corn, P, Tam, AL, Ahrar, K, Rao, P, Sircar, K, Cohen, L, Basu, S, Duan, F, Jindal, S, Zhang, Y, Chen, H, Yadav, SS, Shazer, R, Der-Torossian, H, Allison, JP, Sharma, P, Tannir, NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science translational medicine 14(641), 2022. e-Pub 2022. PMID: 35442707.
Hahn, AW, Lebenthal, J, Genovese, G, Sircar, K, Tannir, NM, Msaouel, P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treatment and Research Communications 33, 2022. e-Pub 2022. PMID: 36174377.
Tang, C, Msaouel, P, Hara, K, Choi, H, Le, V, Shah, AY, Wang, J, Jonasch, E, Choi, S, Nguyen, Q, Das, P, Prajapati, S, Yu, Z, Khan, K, Powell, SF, Murthy, R, Sircar, K, Tannir, NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma. Lancet Oncology 22(12):1732-1739, 2021. e-Pub 2021. PMID: 34717797.
Wilson, NR, Wiele, AJ, Surasi, DS, Rao, P, Sircar, K, Tamboli, P, Shah, AY, Genovese, G, Karam, JA, Wood, CG, Tannir, NM, Msaouel, P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clinical Genitourinary Cancer 19(6):e401-e408, 2021. e-Pub 2021. PMID: 34625389.
Pieretti, AC, Westerman, ME, Childs, A, Millward, NZ, Shapiro, DD, Sircar, K, Rao, P, Jonasch, E, Campbell, M, Tannir, NM, Matin, S, Wood, CG, Karam, JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 39(11):790.e17-790.e23, 2021. e-Pub 2021. PMID: 34301458.
Wiele, AJ, Surasi, DS, Rao, P, Sircar, K, Su, X, Bathala, TK, Shah, AY, Jonasch, E, Cataldo, VD, Genovese, G, Karam, JA, Wood, CG, Tannir, NM, Msaouel, P. Efficacy and safety of bevacizumab plus erlotinib in patients with renal medullary carcinoma. Cancers 13(9), 2021. e-Pub 2021. PMID: 33946504.
Chahoud, J, Msaouel, P, Ross, JA, McCormick, B, Bathala, TK, Gao, J, Horn, R, Xiao, L, Sircar, K, Campbell, M, Shah, AY, Goswami, S, Zurita-Saavedra, A, Jonasch, E, Matin, S, Wood, CG, Karam, JA, Sharma, P, Tannir, NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urologic Oncology: Seminars and Original Investigations 39(2):134.e9-134.e16, 2021. e-Pub 2021. PMID: 33187886.
Shaw, LK, Wiele, AJ, Sircar, K, Wood, CG, Msaouel, P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treatment and Research Communications 27, 2021. e-Pub 2021. PMID: 33725559.
Cowman, SJ, Fuja, D, Liu, X, Tidwell, R, Kandula, N, Sirohi, D, Agarwal, AM, Emerson, L, Tripp, SR, Mohlman, JS, Stonhill, M, Garcia, G, Conley, CJ, Olalde, AA, Sargis, T, Ramirez-Torres, A, Karam, JA, Wood, CG, Sircar, K, Tamboli, P, Boucher, K, Maughan, B, Spike, BT, Ho, TH, Agarwal, N, Jonasch, E, Koh, MY. Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research 26(18):4970-4982, 2020. e-Pub 2020. PMID: 32586940.
Ruiz-Cordero, R, Rao, P, Li, L, Qi, Y, Atherton, D, Peng, B, Singh, RR, Kim, T, Kawakami, F, Routbort, MJ, Alouch, N, Chow, CW, Tang, X, Lu, W, Brimo, F, Matin, S, Wood, CG, Tannir, NM, Wistuba, II, Chen, K, Wang, J, Medeiros, LJ, Karam, JA, Tamboli, P, Sircar, K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Modern Pathology 32(11):1698-1707, 2019. e-Pub 2019. PMID: 31231128.
Wang, F, Zhang, S, Kim, T, Lin, Yy, Iqbal, R, Wang, Z, Mohanty, V, Sircar, K, Karam, JA, Wendl, MC, Meric-Bernstam, F, Weinstein, JN, Ding, L, Mills, GB, Chen, K. Integrated transcriptomic–genomic tool Texomer profiles cancer tissues. Nature Methods 16(5):401-404, 2019. e-Pub 2019. PMID: 30988467.
Gilligan, TD, Lin, DW, Aggarwal, R, Chism, D, Cost, NG, Derweesh, IH, Emamekhoo, H, Feldman, DR, Geynisman, DM, Hancock, SL, Lagrange, C, Levine, EG, Longo, T, Lowrance, W, McGregor, BA, Monk, P, Picus, J, Pierorazio, P, Rais-Bahrami, S, Saylor, P, Sircar, K, Smith, DC, Tzou, K, Vaena, D, Vaughn, DJ, Yamoah, K, Yamzon, J, Johnson-Chilla, A, Keller, J, Pluchino, L. Testicular cancer, version 2.2020. JNCCN Journal of the National Comprehensive Cancer Network 17(12):1529-1554, 2019. e-Pub 2019. PMID: 31805523.
Sekino, Y, Sakamoto, N, Goto, K, Honma, R, Shigematsu, Y, Quoc, TP, Sentani, K, Oue, N, Teishima, J, Kawakami, F, Karam, JA, Sircar, K, Matsubara, A, Yasui, W. Uc.416 + A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinoma. BMC cancer 18(1), 2018. e-Pub 2018. PMID: 30286729.
Romero Arenas, MA, Whitsett, TG, Aronova, A, Henderson, SA, LoBello, J, Habra, MA, Grubbs, EG, Lee, JE, Sircar, K, Zarnegar, R, Scognamiglio, T, Fahey, TJ, Perrier, ND, Demeure, MJ. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma. Annals of surgical oncology 25(3):801-807, 2018. e-Pub 2018. PMID: 29218429.
Kawakami, F, Sircar, K, Rodriguez Canales, J, Fellman, B, Urbauer, D, Tamboli, P, Tannir, NM, Jonasch, E, Wistuba, II, Wood, CG, Karam, JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer 123(24):4823-4831, 2017. e-Pub 2017. PMID: 28832979.
Shah, AY, Karam, JA, Malouf, GG, Rao, P, Lim, ZD, Jonasch, E, Xiao, L, Gao, J, Vaishampayan, U, Heng, DY, Plimack, ER, Guancial, E, Fung, C, Lowas, SR, Tamboli, P, Sircar, K, Matin, S, Rathmell, WK, Wood, CG, Tannir, NM. Management and outcomes of patients with renal medullary carcinoma. BJU international 120(6):782-792, 2017. e-Pub 2017. PMID: 27860149.
Wang, Z, Kim, T, Peng, B, Karam, JA, Creighton, CJ, Joon, A, Kawakami, F, Trevisan, P, Jonasch, E, Chow, CW, Rodriguez Canales, J, Tamboli, P, Tannir, NM, Wood, CG, Monzon, FA, Baggerly, KA, Varella-Garcia, M, Czerniak, BA, Wistuba, II, Mills, GB, Shaw, KM, Chen, K, Sircar, K. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape. Clinical Cancer Research 23(21):6686-6696, 2017. e-Pub 2017. PMID: 28710314.
Keskin, SK, Msaouel, P, Hess, KR, Yu, KJ, Matin, S, Sircar, K, Tamboli, P, Jonasch, E, Wood, CG, Karam, JA, Tannir, NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies. Journal of Urology 198(3):530-537, 2017. e-Pub 2017. PMID: 28411072.
Kalra, S, Verma, J, Atkinson, BJ, Matin, S, Wood, CG, Karam, JA, Lin, S, Satcher, R, Tamboli, P, Sircar, K, Rao, P, Corn, P, Tannir, NM, Jonasch, E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clinical Genitourinary Cancer 15(3):363-370, 2017. e-Pub 2017. PMID: 28216278.
Wobker, SE, Przybycin, CG, Sircar, K, Epstein, J. Renal oncocytoma with vascular invasion. Human Pathology 58:1-6, 2016. e-Pub 2016. PMID: 27498062.
Thomas, AZ, Adibi, M, Tidwell, R, Borregales, LD, Merril, MM, Tamboli, P, Sircar, K, Jonasch, E, Tannir, NM, Matin, S, Wood, CG, Karam, JA. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation. Journal of Urology 196(3):678-684, 2016. e-Pub 2016. PMID: 27036304.
Malouf, GG, Ali, SM, Wang, K, Balasubramanian, S, Ross, JS, Miller, VA, Stephens, PJ, Khayat, D, Pal, S, Su, X, Sircar, K, Tamboli, P, Jonasch, E, Tannir, NM, Wood, CG, Karam, JA. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. European urology 70(2):348-357, 2016. e-Pub 2016. PMID: 26895810.
Zheng, S, Cherniack, AD, Dewal, N, Moffitt, RA, Danilova, L, Murray, BA, Lerario, AM, Else, T, Knijnenburg, T, Ciriello, G, Kim, S, Assie, G, Morozova, O, Akbani, R, Shih, J, Hoadley, KA, Choueiri, TK, Waldmann, J, Mete, O, Gordon Robertson, A, Wu, HT, Raphael, BJ, Shao, L, Meyerson, M, Demeure, MJ, Beuschlein, F, Gill, AJ, Sidhu, SB, Almeida, MQ, Fragoso, MC, Cope, L, Kebebew, E, Habra, MA, Whitsett, TG, Bussey, KJ, Rainey, WE, Asa, SL, Bertherat, J, Fassnacht, M, Verhaak, R, Chin, L, Ju, Z, Kim, H, Ling, S, Liu, W, Lu, Y, Mills, GB, Sircar, K, Wang, Q, Weinstein, JN. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer cell 29(5):723-736, 2016. e-Pub 2016. PMID: 27165744.
Kalra, S, Atkinson, BJ, Matrana, MR, Matin, S, Wood, CG, Karam, JA, Tamboli, P, Sircar, K, Rao, P, Corn, P, Tannir, NM, Jonasch, E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU international 117(5):761-765, 2016. e-Pub 2016. PMID: 26032863.
Zhou, L, Liu, X, Sun, M, Zhang, X, German, P, Bai, S, Ding, Z, Tannir, NM, Wood, CG, Matin, S, Karam, JA, Tamboli, P, Sircar, K, Rao, P, Rankin, EB, Laird, DA, Hoang, A, Walker, CL, Giaccia, AJ, Jonasch, E. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35(21):2687-2697, 2016. e-Pub 2016. PMID: 26364599.
Borregales, LD, Kim, DY, Staller, AL, Qiao, W, Thomas, AZ, Adibi, M, Tamboli, P, Sircar, K, Jonasch, E, Tannir, NM, Matin, S, Wood, CG, Karam, JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations 34(5):237.e19-237.e26, 2016. e-Pub 2016. PMID: 26707613.
Tannir, NM, Jonasch, E, Albiges, L, Altinmakas, E, Ng, CS, Matin, S, Wang, X, Qiao, W, Dubauskas Lim, Z, Tamboli, P, Rao, P, Sircar, K, Karam, JA, McDermott, DF, Wood, CG, Choueiri, TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN). European urology 69(5):866-874, 2016. e-Pub 2016. PMID: 26626617.
Ozsari, L, Kutahyalioglu, M, Elsayes, KM, Vicens, RA, Sircar, K, Jazaerly, T, Waguespack, SG, Busaidy, NL, Cabanillas, ME, Dadu, R, Hu, MI, Vassilopoulou-Sellin, R, Jimenez, C, Lee, JE, Habra, MA. Preexisting adrenal masses in patients with adrenocortical carcinoma. Endocrine 51(2):351-359, 2016. e-Pub 2016. PMID: 26206754.
Sircar, K, Yoo, SY, Majewski, T, Wani, K, Patel, L, Voicu, H, Torres-Garcia, W, Verhaak, R, Tannir, NM, Karam, JA, Jonasch, E, Wood, CG, Tamboli, P, Baggerly, KA, Aldape, KD, Czerniak, BA. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. Journal of Pathology: Clinical Research 2(1):212-224, 2016. e-Pub 2016. PMID: 27499906.
Adibi, M, Thomas, AZ, Borregales, LD, Merril, MM, Tidwell, R, Chen, HC, Sircar, K, Murugan, P, Tamboli, P, Jonasch, E, Tannir, NM, Matin, S, Wood, CG, Karam, JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations 33(10):427.e17-427.e23, 2015. e-Pub 2015. PMID: 26004164.
Phan, L, Fuentes-Mattei, E, Wu, W, Velazquez-Torres, G, Sircar, K, Wood, CG, Hai, T, Jimenez, C, Cote, G, Ozsari, L, Hofmann, M, Zheng, S, Verhaak, R, Pagliaro, LC, Cortez, MA, Lee, M, Yeung, SJ, Habra, MA. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Research 75(19):4131-4142, 2015. e-Pub 2015. PMID: 26282167.
Singh, RR, Murugan, P, Patel, L, Voicu, H, Yoo, SY, Majewski, T, Mehrotra, M, Wani, K, Tannir, NM, Karam, JA, Jonasch, E, Wood, CG, Creighton, CJ, Medeiros, LJ, Broaddus, R, Tamboli, P, Baggerly, KA, Aldape, KD, Czerniak, BA, Luthra, R, Sircar, K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma. Modern Pathology 28(9):1225-1235, 2015. e-Pub 2015. PMID: 26111976.
Liu, X, Hoang, A, Zhou, L, Kalra, S, Yetil, A, Sun, M, Ding, Z, Zhang, X, Bai, S, German, P, Tamboli, P, Rao, P, Karam, JA, Wood, CG, Matin, S, Zurita-Saavedra, A, Bex, A, Griffioen, AW, Gao, J, Sharma, P, Tannir, NM, Sircar, K, Jonasch, E. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma. Cancer Immunology Research 3(9):1017-1029, 2015. e-Pub 2015. PMID: 26014097.
Vodopivec, DM, Habra, MA, Ng, CS, Sircar, K, Grubbs, EG. Visual Vignette. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 21(7):854, 2015. e-Pub 2015. PMID: 26121444.
Merril, MM, Wood, CG, Tannir, NM, Tidwell, R, Babaian, KN, Jonasch, E, Pagliaro, LC, Compton, ZR, Tamboli, P, Sircar, K, Pisters, LL, Matin, S, Karam, JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations 33(4):166.e21-166.e29, 2015. e-Pub 2015. PMID: 25700975.
Shawa, H, Elsayes, KM, Javadi, S, Sircar, K, Jimenez, C, Habra, MA. Clinical and radiologic features of pheochromocytoma/ganglioneuroma composite tumors. Endocrine Practice 20(9):864-869, 2014. e-Pub 2014. PMID: 24641930.
Xu, B, Abourbih, S, Sircar, K, Kassouf, W, Aprikian, AG, Tanguay, S, Brimo, F. Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma. Applied Immunohistochemistry and Molecular Morphology 22(3):206-212, 2014. e-Pub 2014. PMID: 23702650.
Ayala-Ramirez, M, Jasim, S, Feng, L, Ejaz, S, Deniz, F, Busaidy, NL, Waguespack, SG, Naing, A, Sircar, K, Wood, CG, Pagliaro, LC, Jimenez, C, Vassilopoulou-Sellin, R, Habra, MA. Adrenocortical carcinoma. European journal of endocrinology 169(6):891-899, 2013. e-Pub 2013. PMID: 24086089.
Abourbih, S, Sircar, K, Tanguay, S, Kassouf, W, Aprikian, AG, Mansure, J, Brimo, F. Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma. World journal of surgical oncology 11, 2013. e-Pub 2013. PMID: 24266898.
Xu, B, Abourbih, S, Sircar, K, Kassouf, W, Mansure, J, Aprikian, AG, Tanguay, S, Brimo, F. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma. Archives of Pathology and Laboratory Medicine 137(10):1326-1336, 2013. e-Pub 2013. PMID: 24079759.
Dayyani, F, Pettaway, CA, Kamat, A, Munsell, M, Sircar, K, Pagliaro, LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urologic Oncology: Seminars and Original Investigations 31(7):1171-1177, 2013. e-Pub 2013. PMID: 22534087.
Dayyani, F, Czerniak, BA, Sircar, K, Munsell, M, Millikan, RE, Dinney, CP, Siefker-Radtke, AO. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. Journal of Urology 189(5):1656-1661, 2013. e-Pub 2013. PMID: 23159581.
Choucair, KA, Guérard, KP, Ejdelman, J, Chevalier, S, Yoshimoto, M, Scarlata, E, Fazli, L, Sircar, K, Squire, JA, Brimo, F, Cunha, IW, Aprikian, AG, Gleave, ME, Lapointe, J. The 16p13.3 (PDPK1) genomic gain in prostate cancer. Translational Oncology 5(6):453-460, 2012. e-Pub 2012. PMID: 23401739.
Brimo, F, Sircar, K, Chevalier, S, Saad, F, Lacombe, L, Têtu, B, Scarlata, E, Aprikian, AG. Banking of fresh-frozen prostate tissue using the alternate mirror image protocol. Cell and Tissue Banking 13(4):631-638, 2012. e-Pub 2012. PMID: 22200970.
Chuang, HH, Deniz, F, Sircar, K, Jimenez, C, De Celis, CR, Wood, CG, Habra, MA. [ 18F]fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma. Journal of Clinical Oncology 30(26):e246-e249, 2012. e-Pub 2012. PMID: 22649135.
Fritsche, HM, Novara, G, Burger, M, Gupta, A, Matsumoto, K, Kassouf, W, Sircar, K, Zattoni, F, Walton, TJ, Tritschler, S, Baba, S, Bastian, PJ, Martinez-Salamanca, JI, Seitz, C, Otto, W, Wieland, WF, Karakiewicz, PI, Ficarra, V, Hartmann, A, Shariat, SF. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 30(5):666-672, 2012. e-Pub 2012. PMID: 20933445.
Shariat, SF, Zigeuner, R, Rink, M, Margulis, V, Hansen, J, Kikuchi, E, Kassouf, W, Raman, JD, Remzi, M, Koppie, TM, Bensalah, K, Guo, CC, Mikami, S, Sircar, K, Ng, C, Haitel, A, Kabbani, W, Chun, FK, Wood, CG, Scherr, DS, Karakiewicz, PI, Langner, C. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival. European urology 62(2):224-231, 2012. e-Pub 2012. PMID: 22285763.
Rink, M, Robinson, B, Green, DA, Cha, EK, Hansen, J, Comploj, E, Margulis, V, Raman, JD, Ng, C, Remzi, M, Bensalah, K, Kabbani, W, Haitel, A, Rioux-Leclercq, N, Guo, CC, Chun, FK, Kikuchi, E, Kassouf, W, Sircar, K, Sun, M, Sonpavde, G, Lotan, Y, Pycha, A, Karakiewicz, PI, Scherr, DS, Shariat, SF. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. Journal of Urology 188(2):398-404, 2012. e-Pub 2012. PMID: 22698626.
Bismar, TA, Yoshimoto, M, Duan, Q, Liu, S, Sircar, K, Squire, JA. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology 60(4):645-652, 2012. e-Pub 2012. PMID: 22260502.
Sircar, K, Huang, H, Hu, L, Cogdell, D, Dhillon, J, Tzelepi, V, Efstathiou, E, Koumakpayi, IH, Saad, F, Luo, D, Bismar, TA, Aparicio, A, Troncoso, P, Navone, NM, Zhang, W. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. American Journal of Pathology 180(3):895-903, 2012. e-Pub 2012. PMID: 22245216.
Sircar, K, Huang, H, Hu, L, Liu, Y, Dhillon, J, Cogdell, D, Aprikian, AG, Efstathiou, E, Navone, NM, Troncoso, P, Zhang, W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PloS one 7(2), 2012. e-Pub 2012. PMID: 22363599.
Yoshimoto, M, Ludkovski, O, Degrace, D, Williams, JL, Evans, AJ, Sircar, K, Bismar, TA, Nuin, P, Squire, JA. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes and Cancer 51(2):149-160, 2012. e-Pub 2012. PMID: 22045666.
Tzelepi, V, Zhang, J, Lu, JF, Kleb, B, Wu, G, Wan, X, Hoang, A, Efstathiou, E, Sircar, K, Navone, NM, Troncoso, P, Liang, S, Logothetis, CJ, Maity, S, Aparicio, A. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clinical Cancer Research 18(3):666-677, 2012. e-Pub 2012. PMID: 22156612.
Zhang, HM, Perrier, ND, Grubbs, EG, Sircar, K, Ye, Z, Lee, JE, Ng, CS. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clinical Radiology 67(1):38-46, 2012. e-Pub 2012. PMID: 21783181.
Youssif, TA, Fahmy, MA, Koumakpayi, IH, Ayala, F, Al Marzooqi, S, Chen, G, Tamboli, P, Squire, JA, Tanguay, S, Sircar, K. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117(2):290-300, 2011. e-Pub 2011. PMID: 20830770.
Rickman, DS, Chen, YB, Banerjee, S, Pan, Y, Yu, J, Vuong, T, Perner, S, Lafargue, CJ, Mertz, KD, Setlur, SR, Sircar, K, Chinnaiyan, AM, Bismar, TA, Rubin, MA, Demichelis, F. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12(12):1031-1040, 2010. e-Pub 2010. PMID: 21170267.
Gorlov, IP, Sircar, K, Zhao, H, Maity, S, Navone, NM, Gorlova, OY, Troncoso, P, Pettaway, CA, Byun, J, Logothetis, CJ. Prioritizing genes associated with prostate cancer development. BMC cancer 10, 2010. e-Pub 2010. PMID: 21044312.
Zigeuner, R, Shariat, SF, Margulis, V, Karakiewicz, PI, Roscigno, M, Weizer, A, Kikuchi, E, Remzi, M, Raman, JD, Bolenz, C, Bensalah, K, Capitanio, U, Koppie, TM, Kassouf, W, Sircar, K, Patard, JJ, Fernandez, M, Wood, CG, Montorsi, F, Ströbel, P, Wheat, JC, Haitel, A, Oya, M, Guo, CC, Ng, C, Chade, DC, Sagalowsky, AI, Langner, C. Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. European urology 57(4):575-581, 2010. e-Pub 2010. PMID: 19959276.
Al-Otaibi, MF, Youssif, TA, Alkhaldi, A, Sircar, K, Kassouf, W, Aprikian, AG, Mulder, D, Tanguay, S. Renal cell carcinoma with inferior vena caval extention. BJU international 104(10):1467-1470, 2009. e-Pub 2009. PMID: 19388993.
Sircar, K, Yoshimoto, M, Monzon, FA, Koumakpayi, IH, Katz, RL, Khanna, A, Alvarez, K, Chen, G, Darnel, AD, Aprikian, AG, Saad, F, Bismar, TA, Squire, JA. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. Journal of Pathology 218(4):505-513, 2009. e-Pub 2009. PMID: 19402094.
Aldousari, S, Sircar, K, Kassouf, W. Plasmacytoid urothelial carcinoma of the bladder. Cases Journal 2(4), 2009. e-Pub 2009.
Darnel, AD, Behmoaram, E, Vollmer, RT, Corcos, J, Bijian, K, Sircar, K, Su, J, Jiao, J, Alaoui-Jamali, MA, Bismar, TA. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clinical Cancer Research 15(4):1376-1383, 2009. e-Pub 2009. PMID: 19228738.
Szymanski, KM, Baazeem, A, Sircar, K, Tanguay, S, Kassouf, W. Primary renal carcinoid tumour with inferior vena caval tumour thrombus. Journal of the Canadian Urological Association 3(3):E7-E9, 2009. e-Pub 2009.
Al-Otaibi, MF, Ross, P, Fahmy, N, Jeyaganth, S, Trottier, H, Sircar, K, Bégin, L, Souhami, L, Kassouf, W, Aprikian, AG, Tanguay, S. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113(2):286-292, 2008. e-Pub 2008. PMID: 18484590.
Diallo, JS, Aldejmah, A, Mouhim, AF, Fahmy, MA, Koumakpayi, IH, Sircar, K, Bégin, L, Mes-Masson, AM, Saad, F. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens. BJU international 101(10):1302-1309, 2008. e-Pub 2008. PMID: 18294307.
Sircar, K, Gottlieb, B, Alvarado, C, Aprikian, AG, Beitel, LK, Alam-Fahmy, M, Bégin, L, Trifiro, M. Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues. Prostate Cancer and Prostatic Diseases 10(4):360-368, 2007. e-Pub 2007. PMID: 17440439.
Diallo, JS, Aldejmah, A, Mouhim, AF, Péant, B, Fahmy, MA, Koumakpayi, IH, Sircar, K, Bégin, L, Mes-Masson, AM, Saad, F. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clinical Cancer Research 13(23):7044-7052, 2007. e-Pub 2007. PMID: 18056181.
Mujoomdar, A, Maheshwari, S, Zand, KR, Sircar, K, Mesurolle, B. Sonographic diagnosis of a ruptured intratesticular pseudoaneurysm secondary to orchitis. American Journal of Roentgenology 189(1):136, 2007. e-Pub 2007. PMID: 17579129.
Binsaleh, S, Sircar, K, Elhilali, M, Anidjar, M. BCG for upper-tract transitional-cell carcinoma. Journal of Endourology 20(12):1068-1071, 2006. e-Pub 2006. PMID: 17206904.
Chen, G, Sircar, K, Aprikian, AG, Potti, A, Goltzman, D, Rabbani, SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107(2):289-298, 2006. e-Pub 2006. PMID: 16752412.
Sircar, K, Gaboury, L, Ouadi, L, Mecteau, M, Scarlata, E, Saad, F, Aprikian, AG, Tanguay, S, Lapointe, S, Lussier, C, Miletti, T, Lanoix, J. Isolation of human prostatic epithelial plasma membranes for proteomics using mirror image tissue banking of radical prostatectomy specimens. Clinical Cancer Research 12(14 Pt 1):4178-4184, 2006. e-Pub 2006. PMID: 16857789.
Alvarado, C, Beitel, LK, Sircar, K, Aprikian, AG, Trifiro, M, Gottlieb, B. Somatic mosaicism and cancer. Cancer Research 65(18):8514-8518, 2005. e-Pub 2005. PMID: 16166332.
Zakian, KL, Sircar, K, Hricak, H, Chen, HN, Shukla-Dave, A, Eberhardt, S, Muruganandham, M, Ebora, L, Kattan, MW, Reuter, V, Scardino, PT, Koutcher, JA. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234(3):804-814, 2005. e-Pub 2005. PMID: 15734935.
Chen, G, Shukeir, N, Potti, A, Sircar, K, Aprikian, AG, Goltzman, D, Rabbani, SA. Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma. Cancer 101(6):1345-1356, 2004. e-Pub 2004. PMID: 15316903.
Binsaleh, S, Sircar, K, Chan, PT. Feasibility of simultaneous testicular microdissection for sperm retrieval and ipsilateral testicular tumor resection in azoospermic men. Journal of andrology 25(6):867-871, 2004. e-Pub 2004. PMID: 15477357.
Al-Assiri, M, Al-Otaibi, MF, Sircar, K, Laplante, M. Renal pelvis squamous cell carcinoma and renal cell carcinoma in a tuberculous kidney. TheScientificWorldJournal 4:965-968, 2004. e-Pub 2004. PMID: 15578119.
Zakian, KL, Eberhardt, S, Hricak, H, Shukla-Dave, A, Kleinman, S, Muruganandham, M, Sircar, K, Kattan, MW, Reuter, V, Scardino, PT, Koutcher, JA. Transition zone prostate cancer. Radiology 229(1):241-247, 2003. e-Pub 2003. PMID: 12920178.
Yossepowitch, O, Sircar, K, Scardino, PT, Ohori, M, Kattan, MW, Wheeler, TM, Reuter, V. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. Journal of Urology 168(5):2011-2015, 2002. e-Pub 2002. PMID: 12394697.
Huizinga, JD, Berezin, I, Sircar, K, Hewlett, BR, Donnelly, G, Bercik, P, Ross, C, Algoufi, T, Fitzgerald, P, Der, T, Riddell, R, Collins, SM, Jacobson, K. Development of interstitial cells of Cajal in a full-term infant without an enteric nervous system. Gastroenterology 120(2):561-567, 2001. e-Pub 2001. PMID: 11159897.
Robinson, TL, Sircar, K, Hewlett, BR, Chorneyko, K, Riddell, R, Huizinga, JD. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. American Journal of Pathology 156(4):1157-1163, 2000. e-Pub 2000. PMID: 10751339.
Sircar, K, Hewlett, BR, Huizinga, JD, Chorneyko, K, Berezin, I, Riddell, R. Interstitial cells of cajal as precursors of gastrointestinal stromal tumors. American Journal of Surgical Pathology 23(4):377-389, 1999. e-Pub 1999. PMID: 10199467.

Review Articles

Hwang, MJ, Brennan, P, Monge, BM, Alkamachi, B, Rohra, P, Peshoff, MM, Sharma, P, Sircar, K, Tamboli, P, Rao, P. Best practices and recommendations for grossing and reporting of post-immunotherapy nephrectomy specimens. Diagnostic Histopathology 30(5):275-281, 2024. e-Pub 2024.
Subbiah, V, Sircar, K. Personalizing precision oncology. JNCCN Journal of the National Comprehensive Cancer Network 17(7):886-888, 2019. e-Pub 2019. PMID: 31319384.
Motzer, RJ, Jonasch, E, Agarwal, N, Beard, CJ, Bhayani, S, Bolger, GB, Chang, SS, Choueiri, TK, Costello, BA, Derweesh, IH, Gupta, S, Hancock, SL, Kim, JJ, Kuzel, TM, Lam, ET, Lau, C, Levine, EG, Lin, DW, Michaelson, MD, Olencki, T, Pili, R, Plimack, ER, Rampersaud, EN, Redman, BG, Ryan, CJ, Sheinfeld, J, Shuch, B, Sircar, K, Somer, B, Wilder, RB, Dwyer, M, Kumar, R. Testicular cancer, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network 13(6):772-799, 2015. e-Pub 2015. PMID: 26085393.
Motzer, RJ, Jonasch, E, Agarwal, N, Beard, CJ, Bhayani, S, Bolger, GB, Chang, SS, Choueiri, TK, Costello, BA, Derweesh, IH, Gupta, S, Hancock, SL, Kim, JJ, Kuzel, TM, Lam, ET, Lau, C, Levine, EG, Lin, DW, Michaelson, MD, Olencki, T, Pili, R, Plimack, ER, Rampersaud, EN, Redman, BG, Ryan, CJ, Sheinfeld, J, Shuch, B, Sircar, K, Somer, B, Wilder, RB, Dwyer, M, Kumar, R. Kidney cancer, version 3.2015. JNCCN Journal of the National Comprehensive Cancer Network 13(2):151-159, 2015. e-Pub 2015. PMID: 25691606.
Motzer, RJ, Jonasch, E, Agarwal, N, Beard, CJ, Bhayani, S, Bolger, GB, Chang, SS, Choueiri, TK, Derweesh, IH, Gupta, S, Hancock, SL, Kim, JJ, Kuzel, TM, Lam, ET, Lau, C, Levine, EG, Lin, DW, Margolin, K, Michaelson, MD, Olencki, T, Pili, R, Plimack, ER, Rampersaud, EN, Redman, BG, Ryan, CJ, Sheinfeld, J, Sircar, K, Somer, B, Wang, J, Wilder, RB, Dwyer, M, Kumar, R. Kidney cancer, version 2.2014. JNCCN Journal of the National Comprehensive Cancer Network 12(2):175-182, 2014. e-Pub 2014. PMID: 24586079.
Sircar, K, Rao, P, Jonasch, E, Monzon, FA, Tamboli, P. Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chinese Journal of Cancer 32(6):303-311, 2013. e-Pub 2013. PMID: 23237216.
Pagliaro, LC, Tannir, NM, Sircar, K, Jonasch, E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert review of anticancer therapy 11(6):913-920, 2011. e-Pub 2011. PMID: 21707288.

Abstracts

Bernieh A, Stewart J, Wang Q, Wang J, Sircar K. Adult's Wilms Tumor: Twenty-Year Experience of a Tertiary Cancer Center with Clinicopathological and Molecular Annotation. United States and Canadian Academy of Pathologists 105(3), 2025. e-Pub 2025.
Zhang M, Vikram R, Sircar K, Troncoso P, Guo C, Tamboli P, Czerniak B. Primary Adenocarcinoma of the Urethra: A Clinicopathologic Study of 48 Cases. United States and Canadian Academy of Pathologists 105(3), 2025. e-Pub 2025.
Kumar G, Ruiz-Cordero R, Akgul M, Murugan P, Shen S, Brimo F, Rao P, Tamboli P, Crieghton C, Bhat K, Karam J, Kannan K, Sircar K. Gene Expression Signatures From FFPE Tumor Samples Can Predict For Clinically Indolent Renal Oncocytic Tumors. USCAP 113th Annual Meeting Bringing Education To LIfe 104(3):S982-83, 2024. e-Pub 2024.
Ebare K, Wang G, Wang Q, Nair V, Sathwik Iyer, Rao P, Tamboli P, Kannan K, Wang J, Karam J, Soleimani M, Bhat K, Sircar K. Spatial Transcriptomic Evaluation of Tumor and Tumor Microenvironment of Renal Cell Carcinoma With Respect to Regional Histology And Response To Immunotherapy. USCAP 113th Annual Meeting Bringing Education to Life 104(3):S940-42, 2024. e-Pub 2024.
Alkamachi B, Hwang M, Sircar K, Peshoff M, Tamboli P, Rao P. Best Practices for Grossing and Reporting of Post-immunotherapy Nephrectomy Specimens: A Single Institution Experience of 70 Cases. 112th USCAP Annual Meeting 103(3), 2023. e-Pub 2023.
Nair V, Tian XJ, Noorbakhsh C, Lee Y, Hwang M, Wang, J, Wang ZX, Chen K, Karam JA, Kannan K, Bhat K, Sircar K. Single Region Sampling Does Not Capture the Intra-Tumoral Immune Heterogeneity of Sarcomatoid Renal Cell Carcinoma. Laboratory Investigation. Laboratory Investigation 102(Suppl 1):641-642, 2022. e-Pub 2022.
Ebare K, Lee Y, Christian P, Noorbakhsh C, Tian XJ, Wang J, Kannan K, Bhat K, Karam JA, Sircar K. MAGE Family of Cancer Testis Antigen Genes are Associated with Resistance to Immune Checkpoint Inhibitors in Sarcomatoid Renal Cell Carcinomas 102(1):591-592, 2022. e-Pub 2022.
Alhalabi O, Thouvenin J, Negrier S, Vano YA, Campedel L, Hasanov, E, Bakouny Z, Hahn AW, Bilen MA, Choueiri TK, Viswanathan SR, Sircar K, Albiges L, Malouf G, Tannir NM. Immuno-oncology (IO)combination plus/- VEGF targeted therapy (VEGF TT) in patients (PTS) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study. Journal of Clinical Oncology 40(6), 2022. e-Pub 2022.
Hahn AW, Viscuse PV, Surasi DS, Bathala T, Wiele AJ, Starbuck MW, Campbell MT, Shah AY, Jonasch E, Gao JJ, Alhalabi O, Sircar K, Tannir NM, Msaouel, P. Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint thereapy (ICT): The MD Anderson Cancer experience. Journal of Clinical Oncology 40(6), 2022. e-Pub 2022.
Guo T, Li J, Wani K, Murugan P, Brimo F, Lazar A, Tamboli P, Zhang J, Bhat K, Sircar K. Gene Methylation Patterns of Aggressive Chromophobe Renal Cell Carcinoma 34(2):559, 2021. e-Pub 2021.
Wilson N, Wiele AJ, Surasi DS, Rao P, Sircar K, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy of gemcitabine plus doxorubicin (Gem plus Dox) in patients with renal medullary carcinoma (RMC). Journal of Clinical Onocology 39(6), 2021. e-Pub 2021.
Wiele AJ, Surasi DS, Rao P, Sircar K, Bathala T, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. The efficacy of bevacizumab erlotinib (B plus E)in patients (pts) with renal medullary carcinoma (RMC). Journal of Clinical Oncology 39(6), 2021. e-Pub 2021.
Oramas D, Kim T, Chen K, Rao P, Tamboli P, Karam J, Shapiro D, Sircar K. Response to Immune Checkpoint Therapy and Clinical Outcome is Not Related to Proportion of Sarcomatous Component in Sarcomatoid Renal Cell Carcinoma 100(1):991, 2020. e-Pub 2020.
Hwang, M, Kerns, BJ, Lee Y, Thompson D, Karam J, Rao P, Tamboli P, Bhat K, Sircar K. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era. Laboratory Investigation 100(1):928, 2020. e-Pub 2020.
Msaouel P, Thall PF, Yuan Y, Wang XM, Jonasch E, Gao JJ, Campbell MT, Shah AY, Corn PG, a T, Ahrar K, Rao P, Sircar K, Der-Torossian H, Tannir NM. A phase I/II of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that profressed on prior VEGF-targeted therapy. Journal of Clinical Oncology 38(6), 2020. e-Pub 2020.
Hasanov E, Peterson CB, Matin SF, Wood CG, Sircar K, Tannir NM, Jonasch E. Hypoxia signaling and immune infiltration in a presurgical trial of sunitinib in patients with clear cell renal cell carcinoma (RCC). Journal of Clinical Onocology 37(15), 2019. e-Pub 2019.
Akgul, M, Kim, T, Qi, Y, Alouch, N, Murugan, P, Shen, S, Brim, F, Rao, P, Tamboli, P, Chen, K, Sircar, K. TP53 and PTEN Mutational Status and Outcome Prediction in Chromophobe Renal Cell Carcinoma. Laboratory Investigation 99(1):781, 2019. e-Pub 2019.
Tang, S, Akgul, M, Kim, T, Chen, K, Wang, F, Sircar, K. Manual Estimation of Tumor Purity is Poor Compared to Sequencing Based Estimates. Laboratory Investigation 99(1):1965, 2019. e-Pub 2019.
Akgul M, Kim T, Qi Y, Alouch N, Murugan P, Shen S, Brim F, Rao P, Tamboli P, Chen K, Sircar K. TP53 and PTEN Mutational Status and Outcome Prediction in Chromphobe Renal Cell Carcinoma 99(1):781, 2019.
Tang S, Akgul M, Kim T, Chen K, Wang F, Sircar K. Manual Estimation of Tumor Purity is Poor Compared to Sequencing Based Estimates 99(1):1965, 2019.
Kojima Y, Shang M, Sircar K, Habra M. Potential therapeutic Biomarker profiles in Adrenocortical Carcinomas 99(1), 2019.
Ma SH, Alouch N, Hawkins M, Ruiz-Cordero R, Li LR, Kawakami F, Brimo F, Wang J, Tamboli P, Sircar K, Rao P. Aggressive Chromophobe RCC (ChRCC) Are Molecularly and Immunochemically Separable From Indolent ChRCC. 107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology 98(1), 2018. e-Pub 2018.
Ma S, Alouch N, Hawkins M, Ruiz-Cordero R, Li L, Kawakami F, Brimo F, Wang J, Tamboli P, Sircar K, Rao P. Aggressive Chromophobe RCC (ChRCC) Molecularly and Immunochemically Separable From Indolent ChRCC. Modern Pathology 31(3):361-362, 2018. e-Pub 2018.
Hruska C, Sircar K, Tamboli P, Rao P. Primary Neuroendocrine Tumors of the Kidney: A clinicopathologic analysis of 17 cases. Does the grading system matter?. 107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 98(1):350-350, 2018. e-Pub 2018.
Ruiz-Cordero R, Li LR, Qi Y, Kawakami F, Alouch N, Lu W, Chen K, Brimo F, Wang J, Tamboli P, Rao P, Sircar K. Hybrid Oncocytic Renal Tumors Display A Molecular Profile Intermediate Between Oncocytoma and Chromophobe Renal Cell Carcinoma. 107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology 98(1):380-380, 2018. e-Pub 2018.
Kojima Y, Hruska C, Sircar K, Habra M Zhang M. Adrenal cortical carcinomas: A microsatellite instability-high tumor. 107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology 31(2):357-357, 2018. e-Pub 2018.
Ruiz-Cordero R, Li L, Qi Y, Kawakami F, Alouch N, Lu W, Chen K, Brimo F, Wang, J Tamboli P, Rao P, Sircar K. Hybrid Oncocytic Renal Tumors Display A Molecular Profile Intermediate Between Oncocytoma And Chromophobe Renal Cell Carcinoma. Modern Pathology 31(3):380-380, 2018. e-Pub 2018.
Kawakami F, Sircar K, Tamboli P, Rodriguez-Canales J, Wood CG, Karam JA. Immunohistochemical phenotype analysis of a large series of sarcomatoid renal cell carcinoma. Laboratory Investigation(97):235A, 2017. e-Pub 2017.
Ruiz-Cordero, Rao, P, Tamboli, P, Singh, R, Routbort, MJ, Sircar, K. Characterization of Driver Mutations in Hybrid Renal Oncocytic Tumors. Laboratory Investigation 97:253A, 2017. e-Pub 2017.
Sircar K, Wang, Z, Kim, T, Peng, B, Karam, JA, Creighton, CJ, Chow, C, Canales R, J, Tamboli, P, Mills, G, Shaw, K, Chen, K. Sarcomatoid Clear Cell RCC Shows a Distinct Molecular Pathogenesis and Driver Mutation Profile. Laboratory Investigation 96((S1)):262A, 2016. e-Pub 2016.
Kawakami F, Sircar K, Rodriguez-Canales J, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Expression of PD-1 and PD-L1 in patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). Journal of Clinical Oncology 34(2 SUPPL):1, 2016. e-Pub 2016.
Adibi, M, Thomas, AZ, Borregales, L, Merrill, MM, Sircar, K, Tamboli, P, Slack, R, Chen, HC, Tannir, NM, Jonasch, E, Matin, SF, Wood, CG, Karam, JA. Percentage of sarcomatoid component as a prognostic indicator for survival in sarcomatoid renal cell carcinoma. Journal of Clinical Oncology 33(7 Supplement S #499), 2015. e-Pub 2015.
Singh R, Tamboli P, Czerniak BA, Medeiros LJ, Luthra R, Sircar K. Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma Pose a Challenge for Personalized Cancer Therapy. Laboratory Investigation 95(Supplement 1 #134):259A-260A, 2015. e-Pub 2015.
Sircar, K, Yoo, S-Y, Majewski, T, Patel, L, Voicu, H, Wani, K, Tamboli, P, Baggerly, K, Aldape, K, Czerniak, B. The Epithelioid and Sarcomatoid Components of Sarcomatoid RCC Are Molecularly Similar to Each Other but Distinct from Fuhrman Grade 4 Non-Sarcomatoid RCC. Laboratory Investigation 94(1):261A-261A, 2014. e-Pub 2014.
Murugan, P, Yoo, S-Y, Majewski, T, Voicu, H, Tamboli, P, Baggerly, K, Czerniak, B, Aldape K, Sircar K. Rhabdoid RCC Is Molecularly Distinct from Fuhrman Grade 4 RCC. Laboratory Investigation 94(1):251A-251A, 2014. e-Pub 2014.
Xu B, Abourbih S, Sircar K, Kassouf W, Aprikian A, Tanguay S, Brimo F. Diagnostic and Prognostic Role of Immunohistochemical Expression of Napsin A in Renal Cell Carcinoma: A Study Including 233 Primary and Metastatic Cases. Modern Pathology 26(2):259A-259A, 2013. e-Pub 2013.
Sircar K, Majewski T, Yoo SY, Patel L, Wani K, Tamboli P, Czerniak B, Baggerly K, Aldape K. Sarcomatoid and Rhabdoid RCC Show a Similar, Poor Prognosis Molecular Signature That Is Separable from Non-Sarcomatoid RCC. Modern Pathology 26(2):249A-249A, 2013. e-Pub 2013.
Atherton D, Sircar K, Tamboli P, Rao P. Renal Oncocytic Tumors with Hybrid Features Occurring in a Sporadic Setting: A Clinicopathologic Study of 22 Cases. Laboratory Investigation 93(1):196A-196A, 2013. e-Pub 2013.
Xu B, Abourbih S, Sircar K, Kassouf W, Aprikian A, Tanguay S, Brimo F. Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated with Metastasis and Adverse Clinical Outcome in Clear Cell Renal Cell Carcinoma. Modern Pathology 26(2):259A-260A, 2013. e-Pub 2013.
Sircar K, Majewski T, Wani K, McDonald J, Baggerly K, Tamboli P, Czerniak B, Aldape K. Sarcomatoid Renal Cell Carcinoma Shows a Distinct Transcriptomic Profile That Is Not Associated with Epithelial to Mesenchymal Transition Markers. Modern Pathology 25(Suppl 2 #1013):241A-242A, 2012. e-Pub 2012.
Sircar K, Huang L, Hu Y, Dhillon J, Cogdell D, Aprikiam A, Navone N, Troncoso P, Zhang W. Mitosis Phase Enrichment with Identification of Mitotic Centromere-Associated Kinesin as a Therapeutic Target in Castration-Resistant Prostate Cancer. Modern Pathology 25(Suppl 2 #1012):241A, 2012. e-Pub 2012.
Monzon FA, Alvarez K, Peterson L, Sircar K, Tamboli P, Jonasch E. Chromosomal Imbalances Identify Pathways Associated with Resistance to Antiangiogenic Therapy in Clear Cell Renal Cell Carcinoma. United States & Canadian Academy of Pathology 100th Annual Meeting, 2011. e-Pub 2011.
Sircar K, Huang H, Cogdell D, Dhillion J, Tzelepi V, Navone N, Bismar T, Koumakpayi H, Saad F, Aprikian A, Troncoso P, Zhang W. Asparagine Synthetase Is a Target in Castration Resistant Prostate Cancer. United States & Canadian Academy of Pathology 100th Annual Meeting, 2011. e-Pub 2011.
Squire JA, Ludkovski O, Evans A, Sircar K, Bismar T, Yoshimoto M. Detection of Genomic Deletions with Higher Sensitivity and Specificity in Formalin Fixed Paraffin Embedded Tissue Samples Using Fluorescence In Situ Hybridization. Journal of Molecular Diagnostics 12(6):910-911, 2010. e-Pub 2010.
Sircar K, Cogdell D, Dhillon J, Huang H, Hu L, Navone N, Katz R, Khanna A, Bismar TA, Koumakpayi IH, Saad F, Aprikian AG, Monzon FA, Troncoso P, Zhang W. Integrative Molecular Profiling of Castration Resistant Prostate Cancer. Modern Pathology 23(Suppl 1 #981):220A, 2010. e-Pub 2010.
Monzon FA, Alvarez K, Sircar K, Tamboli P, Jonasch E. Virtual Karyotyping with SNP Arrays Identifies Chromosomal Imbalances as Biomarkers for Tumor Progression in Clear Cell Renal Cell Carcinoma. Modern Pathology 23(Suppl 1 #925):208A, 2010. e-Pub 2010.
Alshalalfa M, Bakkar A, Sircar K, Squire JA, Alhajj R, Bimar TA. Molecular Pathways Associated with ERG Rearranged PTEN Deleted Hormone Refractory Prostate Cancer. Modern Pathology 23(1):175A-175A, 2010. e-Pub 2010.
Bakkar A, Yoshimoto M, Liu S, Duan Q, Sircar K, Squire JA, Bismar TA. Characterization of ERG Rearrangements, PTEN and SPINK1 Expression in Hormone Refractory Prostate Cancer Associated with Lethal Disease. Modern Pathology 23(1 #782):177A-177A, 2010. e-Pub 2010.
Monzon FA, Alvarez K, Sircar K, Tamboli P, Jonasch E. Virtual Karyotyping with SNP Arrays Identifies Chromosomal Imbalances as Biomarkers for Tumor Progression in Clear Cell Renal Cell Carcinoma. Modern Pathology 23(Suppl. 1 #925):208A-208A, 2010. e-Pub 2010.
Capitanio U, Karakiewicz PI, Margulis V, Raman JD, Lotan Y, Kassouf W, Ziqeuner RE, Roscigno M, Remzi M, Bolenz C, Langner C, Weizer AZ, Kikuchi E, Montorsi F, Bensalah K, Koppie TM, Fernandes MI, Wheat J, Wood CG, Isbarn H, Oya M, Ng CK, Sircar K, Shariat SF. Laparoscopic Nephroureterectomy Does Not Undermine Cancer Control Outcomes in Selected Patients With Non-Metastatic Upper Tract Urothelial Carcinoma. Journal of Urology 181(4):278-278, 2009. e-Pub 2009.
Rao P, Tamboli P, Tanguay S, Aldape KD, Sircar K. YKL-40 as a Marker of Epithelial to Mesenchymal Transitional in Primary and Metastatic RenalCell Carcinoma. Modern Pathology 22(Suppl 1 #862):190A, 2009. e-Pub 2009.
Sher K, Rao P, Chen G, Guoit MC, Fahmy MA, Tanguay S, Aldape K, Sircar K. Oncofetal (IMP3) and Stem Cell Markers in Primary and Metastatic Renal Cell Carcinoma. Modern Pathology 22(Suppl 1 #876):193A, 2009. e-Pub 2009.
Chen YB, Moss B, Banerjee S, Perner S, Lagargue C, Rickman DS, Sircar K, Bismar TA, Rubin MA, Demichelis F. Molecular Pathways Associated with Hormone Refractory TMPRSS2-ERG Fusion Prostate Cancer. Modern Pathology 22(Suppl 1 #1674):369A-369A, 2009. e-Pub 2009.
Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Jiao J, Alaoui-Jamali MA, Bismar TA. Fascin Regulates Prostate Cancer Cell Invasion and Is Associated with Metastasis and Biochemical Failure in Prostate Cancer. Modern Pathology 22(Suppl 1 #742):165A-165A, 2009. e-Pub 2009.
Rao P, Tamboli P, Tanguay S, Aldape KD, Sircar K. YKL-40 as a Marker of Epithelial to Mesenchymal Transition in Primary and Metastatic Renal Cell Carcinoma. Modern Pathology 22(Suppl 1 #862):190A-190A, 2009. e-Pub 2009.
Abou Youssif TM, Tanguay S, Alam-Fahmy M, Koumakpayi IH, Sircar K. Expression of PI3K/AKT/mTOR pathway in renal cell carcinoma metastases: Correlation with pathologic findings and survival. Journal of Urology 179(4):210-210, 2008. e-Pub 2008.
Feifer A, Al-Otaibi MF, Sircar K, Begin LR, Aprikian AG, Kassouf W, Tanguay S. Pathologic disease progression on repeat transrectal biopsy in a contemporary watchful waiting prostate cancer cohort. Journal of Urology 179(4):195-196, 2008. e-Pub 2008.
Fahmy MA, Al-Marozooqi A, Koumakpayi IH, Chen G, Aboyouef T, Tanguay S, Sircar K. Activation status of the PI3K/AKT/mTOR pathway in metastatic renal cell carcinomas and their matched primary tumors. Modern Pathology 21(Suppl 1 #706):155A, 2008. e-Pub 2008.
Sircar K, Yoshimoto M, Koumakpayi IH, Chen G, Darnell A, Aprikian AG, Saad F, Bismar TA, Squire JA. PTEN gene dosage affects downstream AKT pathway in hormone refractory prostate cancer. Modern Pathology 21(Suppl 1 #832):182A, 2008. e-Pub 2008.
Sircar K, Bernard N, Cuello AC, Saragovi HU, Gold P, Aprikian AG, Moffett S. Novel Anti-PSMA monoclonal antibodies show superior tissue specificity. Modern Pathology 20(Suppl 2, #800):176A, 2007. e-Pub 2007.
Sircar K, Blumenkrantz M, Zlobec I, Chen G, Fahmy M, Aprikian A, Guiot MC. Multiple anti-cancer target expression in hormone refractory prostate cancer. Modern Pathology 20(Suppl 2, #801):176A, 2007. e-Pub 2007.
Huwait HF, Yilmaz A, Sircar K, Trpkov K, Brimo F, Alrefae M, Cheng T, Begin L, Bismar TA. Testicular lymphoma: a clinico-pathologic study of 25 cases. Modern Pathology 19(Suppl 1, #691):153A, 2006. e-Pub 2006.
Sircar K, Gottlieb B, Aprikian A, Beitel L, Trifiro M, Alvarado C. Genetic heterogeneity of androgen sensitive and androgen independent prostate cancer: an analysis of androgen receptor CAG repeat lengths in germline, somatic and hermone refractory prostate cancer tissues. Modern Pathology 19(Suppl 1, #748):162A, 2006. e-Pub 2006.
Sircar K, Gaboury L, Scarlatta E, Mecteau M, Aprikian A, Tanguay S, Fahmy N, Lanoix J. Mirror image tissue banking of radical prostatectomy specimens enables isolation of epithelial plasma membranes for proteomics while preserving pathologic quality of retrieved tissues. Modern Pathology 19(Suppl 1, #747):162a, 2006. e-Pub 2006.
Gottlieb B, Alvarado C, Beitel LK, Sircar K, Aprikian A, Trifiro M. Single locus gene mutations and prostate cancer. Can mutations in the androgen receptor gene be directly linked to the occurrence of prostate cancer?. American Society of Human Genetcs 55th Meeting. Salt Lake City, UT, 2005. e-Pub 2005.
Gottlieb B, Alvarado C, Bietel LK, Sircar K, Aprikian A, Trifiro M. A tumor specific examination into the significance of androgen receptor gene alteration with functional consequences in prostate cancer. Endcrine Society's 87th Annual Meeting. San Diego, CA(#P2-665), 2005. e-Pub 2005.
Chen J, Gokden N, Greene G, Kadlubar FF, Sircar K, Aprikian A, Chen JZ. Implications of mitochondrial DNA modifications in prostate malignancy. The 4th Annual CPC-BioNet Meeting. Vancouver, BC, 2005. e-Pub 2005.
Omeroglu A, Alam M, Tanguay S, Aprikian A, Sircar K. Comparative study of immunohistochemical profiles of fetal and adult nephrons using renal tumor markers. Modern Pathology 18(Suppl 1):157A, 2005. e-Pub 2005.
Sircar K, Alam-Fahmy M, Aprikian A, Beitel L, Gottleib B, Trifiro M, Alvarado C. Androgen receptor CAG tract hetertogeneity in benign and malignant prostatic glands. Modern Pathology 18(Suppl 1):164A, 2005. e-Pub 2005.
Alvarado C, Beitel LK, Sircar K, Aprikian A, Gottlieb B, Trifiro M. Novel somatic changes of the human androgen receptor CAG tract in microdissected specimens from prostate cancer. 12th International Congress of Endocrinology. Lisbon, Porgugal(#P1034), 2004. e-Pub 2004.
Chen G, Shukeir N, Potti A, Sircar K, Goltzman D, Rabbani SA. The Wnt-Beta-catenin pathway is expressed n prostate cancer and in bone metastases. J Bone Miner Res 18(Suppl 2), 2003. e-Pub 2003.
Sircar K, Tickoo SK, Bosl G, Reuter VE. Seminomatious and nonseminomatious differentiaion of mixed germ cell tumours of the testis: an immunohistochemical study of 24 cases. Lab Invest 82(1):757, 2002. e-Pub 2002.
Sircar K, Ohori M, Scardino PT, Reuter VE. Negative repeat biopsy of prostate cancer patients predicts for low volume, low stage disease. Lab Invest 82(1):758, 2002. e-Pub 2002.
Salama S, Sircar K, Hewlett R. Kit expression in melanocytic lesions: an analysis of conventional nevi, spitz and reed's nevi and melanoma. Am J Dermatopath 21(6):595, 1999. e-Pub 1999.
Khan AL, Dodson A, Hewlett BR, Sircar K, Huizinga JD, Riddell RH, Campbell F. Immunohistochemical Investigation of the Role of Interstitial Cells of Cajal in Diverticular Disease. 179th Meeting of the Pathological Society of Great Britain and Ireland. Dundee, Scotland, 1999. e-Pub 1999.
Sircar K, Hewlett BR, Chorneyko K, Riddell RH. Differentiation of diminuitive and partially myoid gut stromal tumors. Lab Invest 79:84A, 1999. e-Pub 1999.
Sircar K, Hewlett B, Riddell RH. Most gastrointestinal stromal tumors (GIST) arise from the interstitial cells of Cajal (ICC). Mod Pathol 11:71A, 1998. e-Pub 1998.

Book Chapters

Guo CC, Zhang M, Sircar K. Tumors of the Renal Pelvis. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. 1st. Springer, 2020.
Sircar K, Tamboli P. Renal Mass Biopsy. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. 1st. Springer, 2020.
Rao, P, Perrino, CM, Zynger, DL, Jorda, M, Tamboli, P, Sanchez, DF, Cubilla, AL, Iczkowski, KA, Zhang, M, Sircar, K. Genitourinary pathology (including adrenal gland). In: Oncologic Surgical Pathology. 1st. Springer, 1523-1726, 2020.
Tamboli P, Sircar K. Renal Cell Carcinoma, Pathologic Considerations. In: Renal Cell Cancer: Principles and Practice. 2nd. Springer, 2015.
Tamboli, P, Sircar, K. Renal Cell Carcinoma, Pathologic Considerations. In: Renal Cell Cancer: Principles and Practice. 1st. Springer, 17-28, 2011.

Letters to the Editor

Huizinga, JD, Berezin, I, Chorneyko, K, Thuneberg, L, Sircar, K, Hewlett, BR, Riddell, R, Kindblom, LG, Meis, JM, Kindblom, LG, Meis- Kindblom, JM. Interstitial cells of Cajal. American Journal of Pathology 153: 2008-2011, 1998.

Less

CV information above last modified March 06, 2026

Kanishka Sircar, M.D.

About Dr. Kanishka Sircar

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Kanishka Sircar, M.D.

About Dr. Kanishka Sircar

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson